Mirum's liver infection drug lowers virus levels in late-stage study

By Reuters News

By Sneha S K

Sept 28 (Reuters) - Mirum Pharmaceuticals MIRM.O on Monday said its experimental hepatitis drug reduced levels of the virus in patients, meeting the main goal of a late-stage study.

Here are some key details:

  • Mirum was testing brelovitug, an experimental monoclonal antibody that binds to the hepatitis B surface antigen, a protein found on the surface of the virus

  • The company was testing the treatment for chronic hepatitis delta virus, a liver infection that affects people already infected with hepatitis B

  • The disease, which the company estimates affects about 230,000 people in the US and Europe, can cause severe symptoms that can lead to liver damage and, in some cases, death

  • At 24 weeks, 56% of patients given 300 milligrams of brelovitug and 45% of those given 900 milligrams showed reduced hepatitis D virus levels and normal liver enzyme levels, compared with 0% in the delayed-treatment group, the company said

  • The company expects the drug to generate peak sales of at least $1 billion

  • The only FDA-approved treatment for the condition is Gilead's GILD.O Hepcludex

  • "Brelovitug has a better benefit/risk profile," said RBC Capital Markets analyst Lisa Walter, adding that the latest results position it as the best-in-class treatment option

  • The drug was well tolerated across dose groups, with a safety profile consistent with previously reported data, Mirum said

  • Full results from the study will be presented at an upcoming medical congress, with the company expecting to submit a marketing application for the drug to the US FDA in the first half of 2027.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.